Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy

Allogeneic CD19-specific chimeric antigen receptor (CAR) T cells with inactivated donor T cell receptor (TCR) expression can be used as an “off-the-shelf” therapeutic modality for lymphoid malignancies, thus offering an attractive alternative to autologous, patient-derived T cells. Current approache...

Descripción completa

Detalles Bibliográficos
Autores principales: Tipanee, Jaitip, Samara-Kuko, Ermira, Gevaert, Thierry, Chuah, Marinee K., VandenDriessche, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552804/
https://www.ncbi.nlm.nih.gov/pubmed/35711141
http://dx.doi.org/10.1016/j.ymthe.2022.06.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552804/
https://www.ncbi.nlm.nih.gov/pubmed/35711141
http://dx.doi.org/10.1016/j.ymthe.2022.06.006

Ejemplares similares